NCT00071006View on ClinicalTrials.gov

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome
Interventions
DRUG

AG-013736 (Axitinib)

patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.

Trial Locations (1)

77030

Pfizer Investigational Site, Houston

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY